日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

No relevant pharmacokinetic interaction between the KRAS G12C inhibitor sotorasib and the direct oral anticoagulant rivaroxaban in healthy subjects

在健康受试者中，KRAS G12C 抑制剂索托拉西布与直接口服抗凝剂利伐沙班之间未发现相关的药代动力学相互作用。

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.70326
Hollander, Esther M; Buma, Alessandra I G; Leentjens, Jenneke; Janssen, Paddy K C; van den Heuvel, Michel M; Burger, David M; Piet, Berber; Ter Heine, Rob
RAS
发表日期：2026
文献求助 收藏

Correction: Model‑Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness

更正：基于模型的皮下注射纳武利尤单抗替代给药策略以提高成本效益

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-026-01627-3
Wang, Yan; Bukkems, Laura H; Ter Heine, Rob; van Hasselt, J G C; Koolen, S L W; Hendrikx, J J M A; Van der Hulle, Tom; Kapiteijn, Ellen; Zwaveling, Juliette; Becker, Annemarie; van den Heuvel, Michel M; Theelen, Willemijn S M E; Oude Munnink, Thijs H; Smit, Egbert F; Guchelaar, Henk-Jan; Moes, Dirk Jan A R
发表日期：2026
文献求助 收藏

Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness

基于模型的皮下注射纳武利尤单抗替代给药策略以提高成本效益

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-025-01610-4
Wang, Yan; Bukkems, Laura H; Ter Heine, Rob; van Hasselt, J G C; Koolen, S L W; Hendrikx, J J M A; Van der Hulle, Tom; Kapiteijn, Ellen; Zwaveling, Juliette; Becker, Annemarie; van den Heuvel, Michel M; Theelen, Willemijn S M E; Oude Munnink, Thijs H; Smit, Egbert F; Guchelaar, Henk-Jan; Moes, Dirk Jan A R
发表日期：2026
文献求助 收藏

Differential effects of C5 inhibition, C3 inhibition, and alternative pathway inhibition on bacterial killing in vitro

C5抑制、C3抑制和替代途径抑制对体外细菌杀灭的不同影响

期刊:Blood Advances
影响因子:7.1
doi:10.1182/bloodadvances.2024013587
Ter Avest, Mendy; de Boer, Zenno; Langemeijer, Saskia M C; van de Kar, Nicole C A J; de Jonge, Marien I; Ter Heine, Rob; Langereis, Jeroen D
微生物学
发表日期：2025
文献求助 收藏

Prospective validation of initial eculizumab dosing in adults with atypical hemolytic uremic syndrome

前瞻性验证依库珠单抗初始剂量在非典型溶血性尿毒综合征成人患者中的应用

期刊:Nephrology Dialysis Transplantation
影响因子:5.6
doi:10.1093/ndt/gfae244
Ter Avest, Mendy; Duineveld, Caroline; Bouwmeester, Romy N; Baas, Laura M; van den Heuvel, Lambertus P W J; Langemeijer, Saskia M C; Wetzels, Jack F M; van de Kar, Nicole C A J; Ter Heine, Rob
发表日期：2025
文献求助 收藏

Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment

叶酸预防和剂量调整可确保肾功能不全患者安全使用培美曲塞治疗。

期刊:Clinical Pharmacology & Therapeutics
影响因子:5.5
doi:10.1002/cpt.3735
de Rouw, Nikki; Otten, Leila-Sophie; Kicken, Mart P; Piet, Berber; Biesma, Bonne; van Veggel, Bianca; Steendam, Christi M J; van den Borne, Ben; Hendriks, Lizza E L; Croes, Sander; Dingemans, Anne-Marie C; Dumoulin, Daphne W; Mathijssen, Ron H J; Burgers, Jacobus A; Huitema, Alwin D R; Derijks, Hieronymus J; Deenen, Maarten J; van den Heuvel, Michel M; Ter Heine, Rob
发表日期：2025
文献求助 收藏

Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer

早期帕博利珠单抗清除率可作为晚期非小细胞肺癌患者无应答的预后生物标志物

期刊:International Journal of Cancer
影响因子:4.7
doi:10.1002/ijc.70052
de Vries, Fenna; Otten, Leila-Sophie; Piet, Berber; Franssen, Eric J F; Smit, Arthur A J; van den Heuvel, Michel M; Ter Heine, Rob
肺癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Eco Friendly and Budget Smart: An Economic and Environmental Evaluation of Alternative PD-1 and PD-L1 Inhibitor Dosing Regimens

环保且经济：PD-1和PD-L1抑制剂替代给药方案的经济和环境评价

期刊:Pharmacoeconomics
影响因子:4.6
doi:10.1007/s40273-025-01535-7
Karlsson, Leo; Ciccolini, Joseph; Ter Heine, Rob; Centanni, Maddalena
PD-L1
PD-1
发表日期：2025
文献求助 收藏

Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria

基于模型指导的依库珠单抗精准给药治疗阵发性睡眠性血红蛋白尿症患者

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-025-01536-x
Ter Avest, Mendy; Langemeijer, Saskia M C; van den Heuvel, Lambertus P W J; Baas, Laura M; van de Kar, Nicole C A J; Ter Heine, Rob
发表日期：2025
文献求助 收藏

TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation

基于治疗药物监测的度伐利尤单抗肺癌患者个体化给药：一项全面的群体药代动力学-药物经济学评价

期刊:Clinical Pharmacokinetics
影响因子:4
doi:10.1007/s40262-025-01555-8
de Vries, Fenna; Franssen, Eric J F; Smit, Arthur A J; Moes, Dirk Jan A R; van der Wekken, Anthonie J; Munnink, Thijs Oude; Hendrikx, Jeroen J M A; Dumoulin, Daphne W; Koolen, Stijn L W; Kievit, Wietske; van den Heuvel, Michel M; Ter Heine, Rob
肺癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏